1. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428-35.
2. Rock KL, Lai J-J, Kono H. Innate and adaptive immune responses to cell death. Immunol Rev. 2011;243(1):191-205.
3. Freire MO, Van Dyke TE. Natural resolution of inflammation. Periodontol 2000. 2013;63(1):149-64.
4. Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, et al. Molecular inflammation: Underpinnings of aging and age-related diseases. Ageing Research Reviews. 2009;8(1):18-30.
5. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177-85.
6. Lai KSP, Liu CS, Rau A, Lanctôt KL, Köhler CA, Pakosh M, et al. Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies. Journal of Neurology, Neurosurgery & Psychiatry. 2017;88(10):876.
7. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, et al. The evolution of vertebrate Toll-like receptors. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(27):9577.
8. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunology. 2001;2(8):675-80.
9. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology. 2013;14(10):1014-22.
10. Gerada C, Ryan KM. Autophagy, the innate immune response and cancer. Mol Oncol. 2020;14(9):1913-29.
11. Patel S. Danger-Associated Molecular Patterns (DAMPs): the Derivatives and Triggers of Inflammation. Current Allergy and Asthma Reports. 2018;18(11):63.
12. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Current Opinion in Immunology. 2005;17(4):338-44.
13. Frevert CW, Felgenhauer J, Wygrecka M, Nastase MV, Schaefer L. Danger- Associated Molecular Patterns Derived From the Extracellular Matrix Provide Temporal Control of Innate Immunity. J Histochem Cytochem. 2018;66(4):213-27.
14. Devarapu SK, Anders H-J. Toll-like receptors in lupus nephritis. J Biomed Sci. 2018;25(1):35-.
15. Cui J, Chen Y, Wang HY, Wang R-F. Mechanisms and pathways of innate immune activation and regulation in health and cancer. Human Vaccines & Immunotherapeutics. 2014;10(11):3270-85.
16. Medvedev AE. Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer. J Interferon Cytokine Res. 2013;33(9):467-84.
17. Sun L, Liu W, Zhang L-J. The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis. J Immunol Res. 2019;2019:1824624-.
18. Sen R. The origins of NF-κB. Nature Immunology. 2011;12(8):686-8.
19. Wullaert A, Bonnet MC, Pasparakis M. NF-κB in the regulation of epithelial homeostasis and inflammation. Cell Res. 2011;21(1):146-58.
20. Tokunaga F, Sakata S-i, Saeki Y, Satomi Y, Kirisako T, Kamei K, et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nature Cell Biology. 2009;11(2):123-32.
21. Solt LA, Madge LA, May MJ. NEMO-binding domains of both IKKalpha and IKKbeta regulate IkappaB kinase complex assembly and classical NF-kappaB activation. J Biol Chem. 2009;284(40):27596-608.
22. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Archiv. 2005;446(5):475-82.
23. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651.
24. Takahashi K, Takeda K, Saiki I, Irimura T, Hayakawa Y. Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential. Cancer Sci. 2013;104(5):558-62.
25. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009;9(4):351-69.
26. Takahashi K, Nagai N, Ogura K, Tsuneyama K, Saiki I, Irimura T, et al. Mammary tissue microenvironment determines T cell-dependent breast cancer-associated inflammation. Cancer Sci. 2015;106(7):867-74.
27. Hardianti B, Umeyama L, Li F, Yokoyama S, Hayakawa Y. Anti‑inflammatory compounds moracin O and P from Morus alba Linn. (Sohakuhi) target the NF‑κB pathway. Mol Med Rep. 2020;22(6):5385-91.
28. Lee HJ, Ryu J, Park SH, Woo E-R, Kim AR, Lee SK, et al. Effects of Morus alba L. and Natural Products Including Morusin on In Vivo Secretion and In Vitro Production of Airway MUC5AC Mucin. Tuberc Respir Dis (Seoul). 2014;77(2):65-72.
29. Jung HW, Kang SY, Kang JS, Kim AR, Woo E-R, Park Y-K. Effect of Kuwanon G Isolated from the Root Bark of Morus alba on Ovalbumin-induced Allergic Response in a Mouse Model of Asthma. Phytotherapy Research. 2014;28(11):1713-9.
30. Paudel P, Seong SH, Wagle A, Min BS, Jung HA, Choi JS. Antioxidant and anti- browning property of 2-arylbenzofuran derivatives from Morus alba Linn root bark. Food Chemistry. 2020;309:125739.
31. Yang Z-G, Matsuzaki K, Takamatsu S, Kitanaka S. Inhibitory effects of constituents from Morus alba var. multicaulis on differentiation of 3T3-L1 cells and nitric oxide production in RAW264.7 cells. Molecules. 2011;16(7):6010-22.
32. Cho D-H, Lim S-T. Germinated brown rice and its bio-functional compounds. Food Chemistry. 2016;196:259-71.
33. Wattanathorn J, Ohnon W, Thukhammee W, Muchmapura S, Wannanon P, Tong- Un T. Cerebroprotective Effect against Cerebral Ischemia of the Combined Extract of Oryza sativa and Anethum graveolens in Metabolic Syndrome Rats. Oxid Med Cell Longev. 2019;2019:9658267-.
34. Kawai T, Akira S. Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity. Immunity. 2011;34(5):637-50.
35. Hirayama D, Iida T, Nakase H. The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis. International Journal of Molecular Sciences. 2018;19(1):92.
36. Watanabe S, Alexander M, Misharin AV, Budinger GRS. The role of macrophages in the resolution of inflammation. The Journal of Clinical Investigation. 2019;129(7):2619- 28.
37. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunology. 2010;11(5):373-84.
38. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochemical and Biophysical Research Communications. 2009;388(4):621-5.
39. Takeda K, Akira S. TLR signaling pathways. Seminars in Immunology. 2004;16(1):3-9.
40. Fitzgerald KA, Kagan JC. Toll-like Receptors and the Control of Immunity. Cell. 2020;180(6):1044-66.
41. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nature Medicine. 2007;13(5):543-51.
42. Joosten LAB, Abdollahi-Roodsaz S, Dinarello CA, O'Neill L, Netea MG. Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. Nature Reviews Rheumatology. 2016;12(6):344-57.
43. Nwet Win N, Hardianti B, Kasahara S, Ngwe H, Hayakawa Y, Morita H. Anti-inflammatory activities of isopimara-8(14),-15-diene diterpenoids and mode of action of kaempulchraols P and Q from Kaempferia pulchra rhizomes. Bioorganic & Medicinal Chemistry Letters. 2020;30(2):126841.
44. Ramani T, Auletta CS, Weinstock D, Mounho-Zamora B, Ryan PC, Salcedo TW, et al. Cytokines: The Good, the Bad, and the Deadly. International Journal of Toxicology. 2015;34(4):355-65.
45. Chambers ES, Vukmanovic-Stejic M. Skin barrier immunity and ageing. Immunology. 2020;160(2):116-25.
46. Matejuk A. Skin Immunity. Arch Immunol Ther Exp (Warsz). 2018;66(1):45-54.
47. Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatologic Therapy. 2004;17(s1):43-8.
48. Yanez DA, Lacher RK, Vidyarthi A, Colegio OR. The role of macrophages in skin homeostasis. Pflugers Arch. 2017;469(3-4):455-63.
49. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-60.
50. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50.
51. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology. 1999;41(3):401-7.
52. Voorhees JJ. Pathophysiology of Psoriasis. Annual Review of Medicine. 1977;28(1):467-73.
53. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. The Journal of Clinical Investigation. 1995;95(1):317-27.
54. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon- γ, Interleukin-2, and Tumor Necrosis Factor-α, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1 a Type 1 Differentiation Bias is also Measured in Circulating Blood T Cells in Psoriatic Patients. Journal of Investigative Dermatology. 1999;113(5):752- 9.
55. Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two differentimmune diseases or one spectrum? Current Opinion in Immunology. 2017;48:68-73.
56. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage. Nature Medicine. 2007;13(2):139-45.
57. Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nature Immunology. 2017;18(6):612-21.
58. Yoshiki R, Kabashima K, Honda T, Nakamizo S, Sawada Y, Sugita K, et al. IL-23 from Langerhans Cells Is Required for the Development of Imiquimod-Induced Psoriasis- Like Dermatitis by Induction of IL-17A-Producing γδ T Cells. Journal of Investigative Dermatology. 2014;134(7):1912-21.
59. Nogueira M, Torres T. Guselkumab for the treatment of psoriasis - evidence to date. Drugs Context. 2019;8:212594-.
60. Krueger JG, Wharton KA, Schlitt T, Suprun M, Torene RI, Jiang X, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. Journal of Allergy and Clinical Immunology. 2019;144(3):750-63.
61. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507-14.
62. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. The Journal of Immunology. 2018;201(6):1605.
63. Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Human vaccines & immunotherapeutics. 2017;13(10):2247-59.
64. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nature Reviews Drug Discovery. 2012;11(10):763-76.
65. van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL- 17 Axis. The Journal of Immunology. 2009;182(9):5836.
66. Moos S, Mohebiany AN, Waisman A, Kurschus FC. Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. Journal of Investigative Dermatology. 2019;139(5):1110-7.
67. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. INNATE IMMUNE RESPONSE IN TH1- AND TH2-DOMINANT MOUSE STRAINS. Shock. 2004;22(5).
68. Mosley Y-YC, Lu F, HogenEsch H. Differences in innate IFNγ and IL-17 responses to Bordetella pertussis between BALB/c and C57BL/6 mice: role of γδT cells, NK cells, and dendritic cells. Immunologic Research. 2017;65(6):1139-49.
69. Sumida H, Yanagida K, Kita Y, Abe J, Matsushima K, Nakamura M, et al. Interplay between CXCR2 and BLT1 Facilitates Neutrophil Infiltration and Resultant Keratinocyte Activation in a Murine Model of Imiquimod-Induced Psoriasis. The Journal of Immunology. 2014;192(9):4361.
70. Hartwig T, Pantelyushin S, Croxford AL, Kulig P, Becher B. Dermal IL-17- producing γδ T cells establish long-lived memory in the skin. European Journal of Immunology. 2015;45(11):3022-33.
71. Katayama M, Sugie S, Yoshimi N, Yamada Y, Sakata K, Qiao Z, et al. Preventive effect of fermented brown rice and rice bran on diethylnitrosoamine and phenobarbital- induced hepatocarcinogenesis in male F344 rats. Oncol Rep. 2003;10(4):875-80.
72. Katyama M, Yoshimi N, Yamada Y, Sakata K, Kuno T, Yoshida K, et al. Preventive effect of fermented brown rice and rice bran against colon carcinogenesis in male F344 rats. Oncol Rep. 2002;9(4):817-22.
73. Kuno T, Hirose Y, Hata K, Kato K, Qiang SH, Kitaori N, et al. Preventive effect of fermented brown rice and rice bran on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats. Int J Oncol. 2004;25(6):1809-15.
74. Kuno T, Nagano A, Mori Y, Kato H, Nagayasu Y, Naiki-Ito A, et al. Preventive Effects of Fermented Brown Rice and Rice Bran against Prostate Carcinogenesis in TRAP Rats. Nutrients. 2016;8(7):421.
75. Phutthaphadoong S, Yamada Y, Hirata A, Tomita H, Taguchi A, Hara A, et al. Chemopreventive effects of fermented brown rice and rice bran against 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in female A/J mice. Oncol Rep. 2009;21(2):321-7.
76. Onuma K, Kanda Y, Suzuki Ikeda S, Sakaki R, Nonomura T, Kobayashi M, et al. Fermented Brown Rice and Rice Bran with Aspergillus oryzae (FBRA) Prevents Inflammation-Related Carcinogenesis in Mice, through Inhibition of Inflammatory Cell Infiltration. Nutrients. 2015;7(12):10237-50.
77. Shibata T, Nagayasu H, Kitajo H, Arisue M, Yamashita T, Hatakeyama D, et al. Inhibitory effects of fermented brown rice and rice bran on the development of acute hepatitis in Long-Evans Cinnamon rats. Oncol Rep. 2006;15(4):869-74.
78. Shibata K, Yamada H, Sato T, Dejima T, Nakamura M, Ikawa T, et al. Notch-Hes1 pathway is required for the development of IL-17–producing γδ T cells. Blood. 2011;118(3):586-93.
79. Nakamura M, Shibata K, Hatano S, Sato T, Ohkawa Y, Yamada H, et al. A Genome-Wide Analysis Identifies a Notch–RBP-Jκ–IL-7Rα Axis That Controls IL-17– Producing γδ T Cell Homeostasis in Mice. The Journal of Immunology. 2015;194(1):243-51.
80. Akitsu A, Iwakura Y. Interleukin-17-producing γδ T (γδ17) cells in inflammatory diseases. Immunology. 2018;155(4):418-26.
81. Wang Y, Li X, Xing X, Xue H, Qi R, Ji H, et al. Notch-Hes1 Signaling Regulates IL- 17A(+) γδ (+)T Cell Expression and IL-17A Secretion of Mouse Psoriasis-Like Skin Inflammation. Mediators Inflamm. 2020;2020:8297134-.
82. Hartupee J, Liu C, Novotny M, Li X, Hamilton T. IL-17 Enhances Chemokine Gene Expression through mRNA Stabilization. The Journal of Immunology. 2007;179(6):4135-41.
83. Witte E, Kokolakis G, Witte K, Philipp S, Doecke W-D, Babel N, et al. IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis. Journal of Investigative Dermatology. 2014;134(11):2757-67.
84. Oka T, Sugaya M, Takahashi N, Nakajima R, Otobe S, Kabasawa M, et al. Increased Interleukin-19 Expression in Cutaneous T-cell Lymphoma and Atopic Dermatitis. Acta Derm Venereol. 2017;97(10):1172-7.
85. Konrad RJ, Higgs RE, Rodgers GH, Ming W, Qian Y-W, Bivi N, et al. Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay. Scientific Reports. 2019;9(1):5211.
86. Chiang C-C, Cheng W-J, Korinek M, Lin C-Y, Hwang T-L. Neutrophils in Psoriasis. Front Immunol. 2019;10:2376-.
87. Chen K, Kolls JK. Interluekin-17A (IL17A). Gene. 2017;614:8-14.
88. Kurschus FC, Moos S. IL-17 for therapy. Journal of Dermatological Science. 2017;87(3):221-7.
89. Qu N, Xu M, Mizoguchi I, Furusawa J-i, Kaneko K, Watanabe K, et al. Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clinical and Developmental Immunology. 2013;2013:968549.
90. Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews. 2020;19(1):102429.
91. Gurczynski SJ, Moore BB. IL-17 in the lung: the good, the bad, and the ugly. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2018;314(1):L6- L16.
92. Sugaya M. The Role of Th17-Related Cytokines in Atopic Dermatitis. International journal of molecular sciences. 2020;21(4):1314.
93. McKinley L, Alcorn JF, Peterson A, DuPont RB, Kapadia S, Logar A, et al. T<sub>H</sub>17 Cells Mediate Steroid-Resistant Airway Inflammation and Airway